Equities

SoftOx Solutions AS

SoftOx Solutions AS

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (NOK)0.0176
  • Today's Change0.002 / 10.00%
  • Shares traded3.12m
  • 1 Year change-98.86%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of NOK
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments7.656.9157
Total Receivables, Net0.957.798.67
Total Inventory000.20
Prepaid expenses------
Other current assets, total--0.00--
Total current assets8.601566
Property, plant & equipment, net0.653.893.49
Goodwill, net--0--
Intangibles, net885959
Long term investments------
Note receivable - long term------
Other long term assets000
Total assets9778128
LIABILITIES
Accounts payable21116.03
Accrued expenses------
Notes payable/short-term debt288.8312
Current portion long-term debt/capital leases------
Other current liabilities, total(0.07)0.620.04
Total current liabilities492118
Total long term debt000.35
Total debt288.8312
Deferred income tax------
Minority interest------
Other liabilities, total46410
Total liabilities956218
SHAREHOLDERS EQUITY
Common stock0.210.210.21
Additional paid-in capital2.15110110
Retained earnings (accumulated deficit)------
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0(94)0
Total equity2.3716110
Total liabilities & shareholders' equity9778128
Total common shares outstanding414040
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.